Overview

3BNC117 and 10-1074 in HIV-infected Individuals

Status:
Completed

Trial end date:
2018-08-15

Target enrollment:

Participant gender:

Summary

This is a phase 1b clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the combination of two anti-human immunodeficiency virus (HIV) broadly neutralizing antibodies, 3BNC117 and 10-1074, administered intravenously in HIV-infected individuals. This study is intended to support the development of the combination of 3BNC117 and 10-1074 mAbs for use in the treatment of HIV-1 infection.

Phase:

Phase 1

Details

Lead Sponsor:

Rockefeller University

Collaborator:

University Hospital of Cologne

Treatments:

Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins